Pediatrix Medical Group, Inc. — FY 2022 Form 10-K
Reporting period: Year ended December 31, 2022; filed February 17, 2023. This is an annual report, not a standalone fourth-quarter report. Pediatrix provides physician services in neonatal, maternal-fetal, pediatric cardiology and other pediatric specialties across 37 states. It changed its name from Mednax in July 2022 and ceased Puerto Rico operations at year-end.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Net revenue | $1,972.0 million | $1,911.2 million |
| Operating income / margin | $172.7 million / 8.8% | $202.9 million / 10.6% |
| Continuing-operations income | $62.6 million | $108.0 million |
| Net income | $66.3 million | $131.0 million |
| Diluted continuing-operations EPS | $0.74 | $1.26 |
| Adjusted EBITDA from continuing operations | $241.0 million | $265.5 million |
| Cash from continuing operating activities | $182.3 million | $113.8 million |
Revenue increased 3.2%, primarily from acquisitions, while same-unit revenue declined $20.6 million, or 1.1%. Same-unit patient-service volume rose 1.6%, but reimbursement-related factors reduced revenue 2.7%. Practice salaries and benefits increased 6.6% to $1.38 billion; general and administrative expense fell 12.1% to $231.4 million.
At year-end, cash and cash equivalents were $9.8 million, short-term investments were $93.2 million, and working capital was $1.0 million, down $412.2 million year over year. Continuing-operations investing cash flow was negative $57.0 million and financing cash flow was negative $487.6 million. Days sales outstanding improved to 53.1 from 55.2.
Debt principal totaled $644.6 million: $400.0 million of fixed-rate senior notes and $244.6 million of variable-rate credit-facility borrowings. The company reported $446.0 million of remaining revolver capacity and stated it expected operating funds, cash and available credit to meet needs for at least 12 months.
Material changes and unusual items
- In February 2022, Pediatrix issued $400 million of 5.375% senior notes due 2030 and entered into a $250 million term loan and a $450 million revolver, using proceeds and cash to redeem $1.0 billion of 6.25% notes due 2027. The refinancing generated a $57.0 million early-extinguishment loss; management cited lower annual note interest expense after refinancing.
- Transformational and restructuring expenses were $27.3 million, up from $22.1 million. They include costs such as position eliminations and consulting.
- CARES Act relief recognized by continuing operations declined to $13.3 million from $26.1 million. The company reported no material operating-result impact from COVID-19 variants in 2021 or 2022, and patient volumes had returned to pre-pandemic levels by year-end 2022.
- The company acquired a pediatric urgent-care practice and a pediatric gastroenterology practice for total consideration of $31.3 million.
- It repurchased 4.5 million shares for $88.5 million during 2022. No cash dividends were paid.
Outlook, risks and contingencies
The filing provides no specific revenue, earnings or cash-flow guidance. Management described plans to pursue acquisitions, organic growth, pediatric primary and urgent care, technology improvements and telehealth, while noting that telehealth reimbursement and regulatory flexibility may change.
- Reimbursement and payor mix: government-program rates are generally lower than commercial rates. The No Surprises Act, Medicaid changes, Medicare payment reductions and payer contract changes may constrain collections or reimbursement.
- Concentration: the five largest states generated about 65% of 2022 net revenue; Texas alone represented about 32%.
- Operating execution: physician recruitment and retention, rising clinical compensation, hospital contract renewals and revenue-cycle-management outsourcing may affect margins and collections. Same-unit reimbursement pressure and higher practice costs contributed to lower operating margin.
- Financial and estimation risks: variable-rate debt exposes earnings to interest-rate changes; a 1% rate change was estimated to affect pretax income by $2.4 million annually. Patient receivable allowances and professional-liability reserves require significant estimates. Professional-liability reserves totaled $307.9 million, with $54.7 million of related insurance receivables.
- Legal and regulatory exposure: the company expects routine government and payer audits but recorded no accrual for future audit matters because potential liabilities could not be reasonably estimated. It also faces malpractice claims and other litigation; outcomes and insurance recoveries are uncertain.
The independent auditor issued an unqualified opinion on the financial statements and internal controls; management and the auditor concluded internal control over financial reporting was effective as of December 31, 2022.
Important facts for investors to verify
- Whether the 2022 decline in same-unit revenue and operating margin stabilizes, and how much results depend on acquisition growth.
- Cash generation and near-term liquidity given $9.8 million of cash, $1.0 million of working capital and substantial year-over-year cash depletion; assess the availability and terms of the revolver.
- Actual reimbursement and collections effects from the No Surprises Act, Medicaid and Medicare policy changes, including independent dispute-resolution outcomes.
- Progress and cost of revenue-cycle-management and other transformation initiatives, and whether adjusted EBITDA improvements translate into GAAP earnings and cash flow.
- Changes in professional-liability reserves, patient-receivable estimates and any developments in government audits or litigation.